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In the light of recent lines of evidence, 5-HT6R ligands are a promising tool for future treatment of
memory impairment. Hence, this study has supplied highly potent 5-HT6R agents with procognitive
effects, which represent an original chemical class of 1,3,5-triazines, different from widely studied sul-
fone and indole-like 5-HT6R ligands. The new compounds were rationally designed as modifications of
lead, 4-(1-(2-chlorophenoxy)ethyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine (1), involving an
introduction of: (i) two chlorines at benzene ring and (ii) varied linkers joining the triazine ring to ar-
omatic ethers. Synthesis, in vitro and in vivo biological tests and computer-aided SAR analysis for 19 new
compounds were carried out. Most of the new triazines displayed high affinity (Ki < 100 nM) and
selectivity towards 5-HT6R, with respect to 5-HT2AR, 5-HT7R and D2R. The crystallography-supported
docking studies, including quantum-polarized ligand docking (QPLD), indicated that chlorine atoms
may be involved in different type of halogen bonding, however, the linker properties seem to pre-
dominately affect the 5-HT6R affinity. 4-[1-(2,5-Dichlorophenoxy)propyl]-6-(4-methylpiperazin-1-yl)-
1,3,5-triazin-2-amine (9), which displayed: the highest affinity (Ki ¼ 6 nM), very strong 5-HT6R antag-
onistic action (KB ¼ 27 pM), procognitive effects in vivo in novel object recognition (NOR) test in rats, a
very good permeability in PAMPA model and satisfying safety in vitro, was identified as the most potent
1,3,5-triazine agent so far, useful as a new lead for further research.
© 2020 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The serotoninergic 5-HT6 receptor was discovered in 1993 as
one of the latest members of serotoninergic system [1], beinger Masson SAS. This is an open accestructurally and pharmacologically different from other subtypes
[2]. As typical G-protein coupled receptor, it stimulates activity of
adenylyl cyclase, which results with cyclic AMP increase. The
attractiveness of this receptor as therapeutic target has been
growing up since many preclinical studies confirmed an efficacy of
the 5-HT6R ligands in serious central nervous system (CNS) dys-
functions, such as: depression [3], Alzheimer’s disease (AD) [4,5],
schizophrenia [6] and obesity [7,8]. Additionally, very recentss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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treatment of irritable bowel syndrome (IBS) [9]. Importantly, both
the 5-HT6R antagonist and agonist, were able to improve memory
impairment in novel object recognition- (NOR), social recognition-
(SRT), Y-maze continuous spontaneous alternation- (Y-CAT) and
Morris water maze (MWM) tests in rats [10,11]. This makes 5-HT6
receptor an intriguing protein target, demanding in-depth research
that leads to elucidation of its mechanism of action.
Despite of a number of already synthesized and pharmacologi-
cally evaluated 5-HT6R ligands, none has been approved as new
drug in pharmaceutical market. Several 5-HT6R agents have
reached clinical trials (Fig. 1) [12e17] but, for the time being, the
clinical experiments have not confirmed clearly either significant
procognitive effects in patients with mild to severe AD or anxiolytic
ones in patients with schizophrenia, thus highlighting a need of
further studies on 5-HT6R-mediated mechanisms of action. Worth
noting, the majority of previously found 5-HT6R ligands, belongs
mainly to two chemical classes, i.e.: indole-derivatives or sulfones
[18]. Given all the mentioned-above facts, a further search for
chemically original 5-HT6R agents, which could be translated into
efficacy in clinical trials, seems to be relevant in terms of rational
strategy for new potential treatment of CNS disorders.
On the other hand, halogen atoms are substituents very widely
used in medicinal chemistry as their introduction into molecules
often results in an improvement of metabolic stability [19], blood-
brain barrier (BBB) penetration [20] or other biological membrane
permeability [21]. Moreover, their presence may provide higher
activity thanks to ability to form non-covalent interactions, so-
called halogen bonding (XB), thus stabilizing protein-ligand com-
plex [22]. The importance of this phenomena has been already
confirmed in search for 5-HT6R antagonists [23], but also for ligands
of other GPCRs (e.g. 5-HT1A [24], 5-HT2BR [25], 5-HT7R [26], D2R,
D4R [27]). Taking into account aforementioned facts, halogen sub-
stituents can be considered as those of the first order in pharma-
comodulation of novel biologically active small molecules.
Intending to explore a new chemical space for 5-HT6R ligands,
our recent research was concentrated on design, synthesis and
pharmacological characteristics of novel, non-indole and non-
sulfone, family of 1,3,5-triazine derivatives to give a group of new
5-HT6R agents with high affinity (Ki < 100 nM) and selectivity for 5-
HT6 receptor [28e31]. The structure-activity relationship (SAR)
analysis for those 1,3,5-triazine 5-HT6R ligands showed aFig. 1. The 5-HT6R antagonists, wsignificant role of their linker and a linker-dependent substitution
in the aromatic system. Thus, the lipophilic substituent in meta
position was conducive to activity in the series of 1,3,5-triazines
with the methylene linker [31]. In the case of the cyclic moiety in
the linker, para substitutionwas the most advantageous [29], while
compounds containing an ether linker were found as the most
interesting group, giving broad possibilities for further modifica-
tions [28,30,32]. In that last group, compound MST4, containing
alkyl substituents at both, 2- and 5-positions of benzene, was the
most active derivative found so far (Ki ¼ 11 nM, Fig. 2) [32]. It is
worth to underline, that alkyl mono-substituted (at the benzene
ring) analogues of MST4 were significantly less active
(Ki ¼ 87e235 nM), while better results were observed for some
chlorine mono-substituted derivatives. Among them, compound
WA-13 (1, Fig. 2), containing o-chlorobenzene and the methyl
branching linker took our special attention, as displaying both
potent (Ki ¼ 23 nM) and selective action on 5-HT6R as well as
satisfying CNS-druglike properties. Furthermore, antidepressant
effect of 1 was confirmed in the forced swim test (FST) in rats [28].
In this context, the compound 1was selected as an appropriate lead
structure for further chemical modifications.
Therefore, this study was focused on design, synthesis and
biological evaluation of novel derivatives of the lead 1, where the
main chemical modifications concerned a variety of chlorine di-
substitutions at the phenyl aromatic ring (R1). Furthermore, mod-
ifications of the linker, i.e. length (n) and branching (R2), were
carried out (Fig. 2). In term to complete SAR analysis, one com-
poundwith the unsubstituted phenyl ring, but branched linker, was
under consideration.
For this purpose, synthesis of 19 new derivatives of WA-13
(2e20, Fig. 2) has been performed. Whole the series (220) was
tested for the affinity and selectivity towards 5-HT6R in the radio-
ligand binding assay (RBA). Selected active compounds have been
evaluated in extended screening, including: (i) their intrinsic ac-
tivity in functional assays, (ii) ADMETox properties in vitro as well
as (iii) behavioral tests in vivo. In order to perform comprehensive
SAR analysis, crystal structures for two representative members
with different length of linkers have been carried out, followed by
molecular modelling, including quantum-polarized ligand docking
(QPLD), with special emphasize on role of halogen bond in ligand-
receptor complexes.hich reached clinical trials.
Fig. 2. The previously reported hit compound (MST4), the lead structure (WA-13, 1) and its chemical modifications investigated within this study.
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2.1. Synthesis
The compounds (220) were obtained within 2-step synthesis
pathways, elaborated on the basis of procedures described for
previous 1,3,5-triazines [13]. In the first step, O-alkylation of com-
mercial (dichloro)phenols with appropriate bromoesters was usedScheme 1. Synthetic route for compounds 2e20. Reagents and conditions: (i) BuOH, reflux, y
Na, reflux 15e30 h, yield: 13e52%.to give aromatic ethers (22e40). Then, the cyclic condensation of 4-
methylpiperazin-1-yl biguanide dihydrochloride (21) with the
adequate ester (22e40) was carried out to form a 1,3,5-triazine ring
resulting in final products 2e20 (Scheme 1). As the racemic mix-
tures of bromoesters were applied for the synthesis of the aromatic
ethers (22e26, 28e31, 33, 34, 36e39), consequently racemic mix-
tures of the final compounds (2e6, 8e11, 13, 14, 16e19) were
obtained.ield: 86%; (ii) acetonitrile, K2CO3, reflux, 2e16 h, yield: 36e90%; (iii) absolute methanol,
Table 1
Radioligand binding assays results for the newly synthesized compounds 2e20.
Compound R1 R2 n Ki [nM]a
5-HT6 5-HT2A 5-HT7 D2
Lead 1 2-Cl Me 0 23 1830 38730 1001
2 H Et 0 21 5047 19940 1506
3 2,3-diCl Me 0 16 268 12550 432
4 2,3-diCl Et 0 6 209 5202 421
5 2,3-diCl Pr 0 23 310 13420 495
6 2,3-diCl n-Bu 0 73 470 5265 506
7 2,3-diCl H 2 274 649 8592 206
8 2,5-diCl Me 0 13 355 15050 375
9 2,5-diCl Et 0 6 484 5706 320
10 2,5-diCl Pr 0 12 382 12470 229
11 2,5-diCl n-Bu 0 17 431 6263 103
12 2,5-diCl H 2 470 1457 7924 413
13 3,4-diCl Me 0 95 576 5928 754
14 3,4-diCl Et 0 86 696 5098 580
15 3,4-diCl H 2 1061 906 4879 356
16 3,5-diCl Me 0 27 412 9398 157
17 3,5-diCl Et 0 11 463 9483 368
18 3,5-diCl Pr 0 26 488 19850 377
19 3,5-diCl n-Bu 0 51 839 10880 270
20 2,4-diCl H 2 999 ntc 1904 ntc
Refb e e e 7 9
a The standard deviation values are reported in Supplementary materials,
Table S2.
b Olanzapine.
c nt e not tested.
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2.2.1. Radioligand binding assays
The binding affinities for all the newly synthesized 1,3,5-triazine
derivatives 2e20 towards the 5-HT6 receptor and competitive ones,
i.e. serotoninergic receptors 5-HT2A, 5-HT7 and dopaminergic D2
receptor, have been assessed in radioligand binding assays
(Table 1).
Serotonin 5-HT2AR and dopaminergic D2R were chosen as pro-
tein off-targets in order to control interactions which might be
responsible for undesired side effects. According to literature,
activation of 5-HT2AR leads to hallucinations [33], whereas inter-
action with D2R is associated with extrapyramidal symptoms (e.g.
acute dystonia and parkinsonian symptoms) [34]. Additionally,
studies on animal models showed that 5-HT7R ligands may cause
procognitive effects [35], similarly as 5-HT6R agents. In order to
clarify, if herein investigated procognitive effects are a result of
interaction with 5-HT6R, the 5-HT7R was also selected as compet-
itive protein target.
According to results obtained, most of the triazine compounds
(2e6, 8e11, 13, 14 and 16e19) showed high affinity for 5-HT6R
(Ki < 100 nM) and significant selectivity, with respect to other
GPCR’s. Ten compounds were more potent than lead structureWA-
13 (Ki < 23 nM). Compounds 4 and 9 turned out to have the highest
5-HT6R affinity (Ki ¼ 6 nM), in 2-fold more potent than the most
active triazine 5-HT6R ligand described so far (MST4, Ki ¼ 11 nM)
[18]. Compound 2 demonstrated the most significant selectivity
towards 5-HT6R, with respect to the rest of considered receptors (5-
HT2AR: 240-fold, 5-HT7R: 950-fold, D2R: 72-fold).2.2.2. Functional assays towards 5-HT6 receptor
Selected active compounds (3, 8, 9,11 and 16)were tested in the
functional assays, in order to study their intrinsic activity towards
5-HT6R. During the experiments, the level of cAMP was measured
(Table 2).
None of the tested derivatives showed agonistic mechanism,
while four out of them showed strong antagonistic action in the
low nanomolar- (3, 8, 16) or even picomolar range in the case of 9
(pKB ¼ 10.57, i.e. KB ¼ 27 pM, Table S3, Supplementary).
2.3. Drug-likeness in vitro
2.3.1. Permeability
For active representatives of the novel triazine derivatives, 8 and
9, permeability was tested using Parallel Artificial Membrane
Permeability Assay (PAMPA). The test is based on compounds’
passive penetration through the bilayer artificial membranes. This
membrane may imitate barriers for compound absorption from the
intestines with a good correlation to in vivo conditions. The assay
was performed in accordance to previously described methods
[36e40]. Both tested ligands (8 and 9) had a high permeability
coefficient (Pe), higher than that forMST4 [32] and compared to Pe
estimated for caffeine, the reference high-permeable compound
(Table 3).
2.3.2. Metabolic stability
The metabolic stability was investigated in vitro by using rat
liver microsomes (RLMs) and supported with MetaSite 6.01 soft-
ware. The most probable structures of metabolites were deter-
mined. In silico predicted sites of metabolism for both compounds 8
and 9 were specified for N-methylpiperazine moiety and para po-
sition of the chlorine di-substituted aromatic ring (Fig. 3).
The incubationwith RLMs for 120 min resulted in the formation
of six (9) or seven (8) metabolites, and more than 90% of each
compound was biotransformed (Table S1; Fig. 4A and B). Obtained
results indicated rather low metabolic stability for both com-
pounds, lower than that forMST4 [32,41], while 9was almost in 3-
fold more stable than 8 (8.93% of 9 vs.3.17% of 8, remained in the
reaction mixture).
These studies allowed us to predict the most probable metabolic
pathway, i.e. the hydroxylation at the phenyl ring (the metabolite
M1), while other probable metabolic pathways included deme-
thylation and hydroxylation of piperazine ring, which were found
for both the 5-HT6R ligands (8, 9) by MS analyses (Table S1;
Figs. S1AeG, Figs. S2AeF, Supplementary).
2.3.3. Toxicity
The safety profile of the 1,3,5-triazine derivatives (8, 9) was
estimated in the hepatotoxicity assay in vitro using hepatoma
HepG2 cell line, according to the protocol reported earlier [37e40].
Both tested compounds 8 and 9 demonstrated a weak hepatotox-
icity effect compared to the used reference toxins (doxorubicin and
3-chlorophenyl-hydrazone). The statistically significant decrease in
cells viability was observed only at the highest applied concen-
tration of compound 8 (100 mM, Fig. 5). Compound 9, due to partial
precipitation at 50 and 100 mM, could be correctly tested only at
lower concentrations, showing no toxicity up to 10 mM, inclusively.
Hence, both compounds (8, 9) displayed a satisfied safety in the
level corresponding to the best derivatives of 1,3,5-triazines tested
previously [28,31,32,38].
2.4. Behavioral studies in vivo
Taking into account that various previously studied 5-HT6 re-
ceptor ligands, especially antagonists, exhibited beneficial effects
Table 2
The results from functional assays for compounds 3, 8, 9, 11 and 16.
Compound Binding affinity pKia Antagonist mode pKBb ± SEM Agonist mode
Emax [%]c ± SEM
SEROTONIN e N.C.d 100 ± 2.0
SB258585 e 8.68 ± 0.055 4 ± 0.5
MIANSERIN e 6.28 ± 0.023 4 ± 0.0
3 7.80 8.24 ± 0.317 4 ± 0.0
8 7.89 8.44 ± 0.138 6 ± 0.5
9 8.22 10.57 ± 0.065 4 ± 0.0
11 7.77 6.36 ± 0.031 4 ± 0.0
16 7.57 8.78 ± 0.332 11 ± 0.5
a Calculated according to the data from Table 1.
b Results were normalized as percentage of reference antagonist (SB258585 105 M).
c Results were normalized as percentage of maximal agonist response (serotonin 105 M); Emax is the maximum possible effect.
d N.C. - not calculable. The full data with standard deviation values are presented in Supplementary materials, Table S3.
Table 3
Permeability coefficient of compounds 8 and 9.
Compound Pea [106 cm/s] ± SD
8 18.0 ± 1.2
9 18.9 ± 0.9
MST4 12.3 ± 2.0
Reference Caffeine 15.1 ± 0.4
a tested in triplicate.
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antagonist in this study, compound 9, has been investigated in two
models of the memory impairment tests, i.e. NOR and NOL (Novel
Object Location) tests. Compound SB-742457, the potent 5-HT6R
antagonist with the confirmed ability to reverse MK-801-induced
memory impairment in NOR test after both, acute and chronic
administrations [10] was used as reference (Fig. 6). The compound
9 dose-depend ameliorated the memory impairment induced by
MK-801 (0.1 mg/kg), in the statistically significant manner at the
dose of 3 mg/kg (Fig. 6a). The obtained data of discrimination index
for the triazine derivative 9 at the dose of 3 mg/kg are comparable
with those for the reference SB-742457 at the same dose used
(Fig. 6a). Despite, we did not observe any activity of this compound
(9) in the NOL test (Fig. 6b).
Thus, the improvement of memory was observed only in the
case of the memory for objects (what) in the NOR but not in the
spatial location (where) in the NOL test. A deficit in episodic
memory is one of the well-established cognitive deficits in
schizophrenic patients and it is the most profound and earliestFig. 3. In silico prediction of the sites of metabolism by MetaSite 8.0.1 for 8 and 9. Blue circ
probability. The fading red color shows the decreasing of the metabolism probability. (For in
Web version of this article.)cognitive deficit in AD [42]. The improved novel object recognition
task, but not the novel location place object preference task,
demonstrates dissociation between the effects of the investigated
compound in a spatial location (NOL test) and the object recogni-
tion (NOR test) version of animal model of episodic memory task.
As this dissociation was obtained using identical stimulus types,
arena, and identical retention delays of 1 h, it cannot be accounted
for by differences in the response requirements of the procedures
or attentional or motivational processes. At this stage of our
research, it is difficult to explain this loss of activity of compound 9
in NOL test. We can only suppose that this compound at the range
of doses used, may possesses ability rather to reverse memory
impairment in recognition than in spatial memory components of
episodic memory, but it needs extended investigations in the
future.
2.5. The computer-aided structure-activity relationship analysis
In order to support structure-activity relationship discussion,
in-depth inside into 3D-structure of the investigated compounds
(220) and their interactions with target 5-HT6R protein in the
molecular level were performed, including both experimental
crystallography and molecular modelling.
2.5.1. Crystallographic studies
Crystallographic analyses for compounds, representing either
the shortest (9) or the longest (20) linker structural category, were
carried out giving a starting point to find active conformations for
the whole series (220) within molecular modelling studies.le marked on the functional group structures indicates the highest biotransformation
terpretation of the references to color in this figure legend, the reader is referred to the
Fig. 4. The UPLC spectra of 8 (A) and 9 (B) and metabolites obtained after 120 min reaction with RLMs.
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numbering schemes are presented in Fig. 7. Both molecules are
isomers possessing the 2-amine-4-(40-methylpiperazin-10-yl)-
1,3,5-triazine moiety, as well as a di-substituted aromatic ring (2,5-
dichloro for 9 and 2,4-dichloro for 20) connected with the triazine
ring by the ethylmetoxylene linker for 9 and the propoxylene linker
for 20. In both molecules the piperazine ring adopts chair confor-
mation with equatorial position of the methyl group. However, the
substituent at the N2 atom is not in a typical equatorial position
with a torsion angle C4eN2eC7eC8 of about 180. The values of
this angle are 111.1(1) and 133.8(1) for 9 and 20, respectively.
These values are lower than in other three crystal structurescontaining the 2-amine-4-(40-methylpiperazin-10-yl)-1,3,5-triazine
moiety [43,44] but similar to one observed in the crystal structure
of the 2-amine-6-(5-chloro-2-methoxyphenyl)-4-(40-methylpiper-
azin-10-yl)-1,3,5-triazine [43], as well as similar to these observed
in the crystal structures of 2-(4-methylpiperazin-1-yl)-1H-imida-
zol-5(4H)-one derivatives [45]. The mutual orientation of three
rings differs in presented crystal structures. The interplanar angles
between triazine and piperazine rings are 43.30(5) and 28.65(5),
while between triazine and aromatic rings are 81.50(4) and
76.62(3) for 9 and 20, respectively.
The intermolecular interactions are similar in both structures.
The main motif of interactions is based on the NeH/N hydrogen
Fig. 5. The effect of tested compounds 8, 9 and references: doxorubicin (DX, 1 mM),
mitochondrial toxin carbonyl cyanide 3-chlorophenyl-hydrazone (CCCP, 10 mM) on
hepatoma HepG2 cell line viability. Compound 9 partly precipitated at 50 and 100
under assay conditions. 1% DMSO in cell growth media was used as a negative control.
GraphPad Prism 8.0.1 was used to calculate the statistical significances by one-way
ANOVA, followed by Bonferroni’s comparison test (****p < 0.0001, **p < 0.01).
S. Sudoł et al. / European Journal of Medicinal Chemistry 203 (2020) 112529 7bonds (Fig. 8). These interactions lead to formation of the dimers. In
addition, the crystal structures are stabilized by NeH/Cl and
CeH$$$p contacts.2.5.2. Molecular modelling
The molecular docking study for the newly synthesized de-
rivatives 2e20 to 5-HT6 receptor homology models showed
coherent binding mode with the previously reported 1,3,5-triazine
derivatives [28e31,41]. The crucial interactions are the salt bridge
between protonated methylpiperazine nitrogen and negatively
charged D3.32 side chain, an aromatic CH...p or p...p interactionFig. 6. Effects of compound 9 on the memory impairment induced by MK-801 in NOR (a) an
801 30 min before the T1 session. The animals were observed for 5 min. The data are prese
ANOVA followed by Bonferroni’s post-hoc test,*p < 0.05,**p < 0.01 vs respective vehicle-tre
ANOVA for discrimination index for NOR test: F(4,30) ¼ 3.99, p < 0.01 (for compound 9) andwith F6.52 and/or F6.51, and hydrogen bond between NH2 group of
1,3,5-triazine ring and carbonyl oxygen of V3.33 and/or A5.42.
Substituted aromatic fragment linked with the 1,3,5-triazine ring
interacted with the hydrophobic cavity formed by transmembrane
domains (TM) 3e5 and extracellular loop 2 (ECL2), moreover, its
positioned into this cavity is caused by the tetrahedral conforma-
tion of the linker. In the light of the molecular docking results, the
comparison of themost active derivative 9with the lead structure 1
(Fig. 9A) showed a retaining of a common binding mode. However,
elongation of the linker caused a decrease of activity, which is in
line with the molecular docking study. For instance, a comparison
of binding modes (Fig. 9A) of compound 9 (Ki ¼ 6 nM) vs. 12
(Ki ¼ 470 nM) showed that too long linker may lead to destabili-
zation of the complex and breaking some key interactions (e.g.with
A5.42/V3.33).
The branching of the linker showed increase of the affinity in
order methyl < ethyl, but decrease in order propyl > butyl for each
of the compared series. Molecular docking indicated (Fig. 9B) that
the branching alkyl group was placed into a small binding cavity
formed by helices 5 and 6, which increased the stability of the
resulting ligandereceptor complexes for shorter, and destabilized
the complexes (perhaps because of the overfilling of this pocket) for
the longer branching group.
In term to investigate the role of different substitution of chlo-
rine atoms in the phenyl fragment, the docking procedure involves
quantum-polarized ligand docking (QPLD) and the MM/GBSA al-
gorithm was used. This procedure showed better performance in
reproducing the X-ray geometries of proteineligand complexes
with halogen bonding than classical docking approach [46], and
was also used to the study of the halogen bonding with privileged
amino acids as an important factormodulating the activity to 5-HT6
receptor [29,47]. The disubstituted series, including: 2,3-diCl (4),
3,5-diCl (17), 2,5-diCl (9), and 3,4-diCl (14) derivatives, and also the
unsubstituted analog (2) in the phenyl fragment (Fig. 9C), was
selected.
It was possible to calculate the changes in the LeR binding free
energy resulting from the substitution of halogen atoms in this
fragment (DDG). Analysis of the binding modes showed thatd NOL (b) tests. Compound 9 and SB-742457 were administered i.p. 60 min, while MK-
nted as the mean ± SEM of 6e8 rats. The data were statistically evaluated by one-way
ated group, and #p < 0.05, ##p < 0.01 vs respective MK-801-treated group. (one-way
F(3,40) ¼ 6.78, p < 0.001 (for SB-742457); and for NOL test: F(4,29) ¼ 2.82, p < 0.05).
Fig. 7. The molecular structures of (a) 9 and (b) 20, showing the atom-numbering schemes. Displacement ellipsoids are drawn at the 50% probability level.
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halogen bonds (all with backbone carbonyl oxygen), which were
also visible in the change of binding free energy and activity of a
given derivative. The highest increase of the binding free energy
was noted for the most active derivatives 4 and 9 (Ki ¼ 6 nM). The
first analogue (2,3-diCl) showed DDG ¼ 2.89 kcal/mol and two
halogen bonds with P4.60 (XB distance ¼ 4.1 Å, s-hole
angle ¼ 165) and A4.56 (XB distance ¼ 3.0 Å, s-hole angle ¼ 141,
with chlorine in position 2). The second derivative (2,5-diCl) dis-
played DDG ¼ 1.96 kcal/mol and halogen bonds with A4.56 (XB
distance ¼ 2.8 Å, s-hole angle ¼ 148) formed by chlorine in po-
sition 2, and surprisingly, with L162 from extracellular loop 2 (XB
distance ¼ 2.7 Å, s-hole angle ¼ 162). The 3,5-diCl analogue 17
showed only slightly lower increase of binding free energy
compared to 2,5-diCl (DDG ¼ 1.78 kcal/mol), for which two
halogen bonds were found as well e with S4.57 (XB
distance ¼ 3.8 Å, s-hole angle ¼ 161), and with L162 (XB
distance ¼ 2.9 Å, s-hole angle ¼ 152) formed by chlorine in po-
sition 5 (as in the 2,5-diCl derivative). The last derivative 14 (3,4-
diCl) showed the lowest increase of binding free energy
equal 0.73 kcal/mol, and only one halogen bond was formed be-
tween chlorine in position 3 with S4.57 (XB distance¼ 3.0 Å, s-hole
angle ¼ 172), whereas the chlorine at position 4 did not show any
specific interaction with the binding site. This analysis demon-
strated that chlorine atoms may be involved in the formation of
halogen bonding, additionally stabilizing the LeR complex, but
their contribution is rather moderate (the highest improvement in
activity after chlorine substitution is approximately 4-fold).2.5.3. General SAR discussion
The chemical modifications of the lead 1 were introduced to
analyze an influence on the affinity towards 5-HT6R of two
following structural factors: (i) dichloro-substitution at phenyl ring
and (ii) the diverse (un)branched linker. The results obtained
within this study allow us to perform comprehensive structure-
activity relationship discussion.
Sixteen out of nineteen newly synthesized compounds
demonstrated a high affinity for 5-HT6R, with Ki values lower than
100 nM. The best pharmacological activity profile was observed for
2,5- and 2,3-dichlorophenoxy 1,3,5-triazine derivatives with a
short but branched alkoxy linker, i.e. compounds 4 (Ki ¼ 6 nM) and
9 (Ki ¼ 6 nM). Both compounds had higher affinity for 5-HT6R than
reference olanzapine as well as the strong picomolar antagonistic
action, found for the 2,5-dichlorophenyl derivative 9
(KB ¼ 0.027 nM), is worth emphasizing. Among the series of ana-
logues with chlorine atoms at the same positions of phenyl ring, a
change of branching in linker, frommethyl to ethyl group, increased
the 5-HT6R affinity, simultaneously maintaining significant selec-
tivity. However, further elongation of branching did not improve
activity, giving the least beneficial effects for the butyl group, which
is consistent with molecular docking results. The mentioned-above
results, together with the high 5-HT6R affinity (Ki ¼ 21 nM) of the
compound unsubstituted at the aromatic ring (2), indicate that the
type of linker is the predominant structural factor for the 5-HT6R
activity of the compounds investigated within this study. This
conclusion may be also supported by previous results, in which the
unbranched analogue of 2 displayed significantly lower affinity for
Fig. 8. The dimers in the crystal structure of 9 (a) and 20 (b). Dashed lines indicates the
hydrogen bonds.
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modelling studies confirmed that chlorine atomsmight be involved
in stabilization of LeR complex through the different type of
halogen bonds, however, their effect on the activity improvement is
moderate. These results allow to fully explain the high and little-
varied activity of branched derivatives ortho-, meta- or unsub-
stituted at the phenyl ring.
On the other hand, the presence of two chlorine substituents at
the phenyl ring was found as profitable also for “drug-like” prop-
erties of the explored 1,3,5-triazines due to an increase of lip-
ophilicity. The higher lipophilicity seems to be desirable to
penetrate membrane barriers, including BBB, which is especially
important in the case of compounds destined to act on CNS. The
representative 2,5-dichlorophenyl derivatives tested (8, 9)
demonstrated high permeability (Pe about 18  106 cm/s) and
rather low risk of hepatotoxicity in the studies in vitro.
Despite the low metabolic stability in vitro, the significant pro-
cognitive effect of the 2,5-dichlorophenyl derivative 9 in vivo was
observed in the NOR test in rats. Furthermore, the active dose of 9
was corresponding to that of compounds MST4 tested previously,although the metabolic stability of MST4 was in 6-fold higher
(59.25% vs. 8.93%), and the 5-HT6R affinity only slightly weaker
(11 nM vs. 6 nM) [32]. The observed procognitive action of com-
pound 9 in vivo seems to be a result of combined factors, i.e. (i) the
beneficial effects of both the highly potent 5-HT6R-antagonistic
action and a putative very good blood-brain barrier penetration
(high permeability confirmed in PAMPA test) on one hand, but (ii)
an unfavorable low metabolic stability effect, on the other. In this
context, the resultant effect indicates a distinctly greater impact of
those favorable factors. Otherwise, the significant activity in the
behavioral test (NOR) could be also caused by synergistic procog-
nitive action of either the compound 9 or the metabolites formed.
However, these hypotheses need wider pharmacological and
ADMET considerations to be enough confirmed.
3. Conclusions
The described herein novel series of 1,3,5-triazine derivatives
enlarged the original family of highly potent 5-HT6R antagonists,
structurally different from widely investigated sulfone and indole-
like compounds. In particular, the systematic modifications of o-
chloro substituted lead (1), via the addition of one more chlorine
substituent and changes within the ether linker, resulted in two the
strongest 5-HT6R agents (4 and 9), in 2-fold more active thanMST4,
the most potent triazine 5-HT6R ligand described so far. Further-
more, the performed elimination of the chlorine-substituent from
the lead 1 gave a potent and highly selective ligand (2), displaying
selectivity for 5-HT6R in the range of 71e867, with respect to 5-
HT2A, 5-HT7 and D2 dopamine receptors. SAR studies supported
by crystallography and extended molecular modelling indicated
that (i) the short linker branched with ethyl chain and (ii) the
dichloro-substituted phenyl ring at positions ortho andmeta are the
most favorable structural factors for strong interaction with the
target 5-HT6R, but the role of the first one is predominant.
The performed study allows to find the new “hit’, i.e. 4-[1-(2,5-
dichlorophenoxy)propyl]-6-(4-methylpiperazin-1-yl)-1,3,5-
triazin-2-amine (9), which displayed extremely high 5-HT6R
antagonistic action in the functional assays, significant procognitive
effects in vivo in rats, very good permeability in PAMPAmodel and a
satisfying safety in vitro. However, the disadvantageous weak
metabolic stability of 9 and its methyl-branched analogue (8) was
indicated in vitro, which requires a further pharmacomodulation.
Apart from compound 9, its 2,3-dichlorophenyl analogue (4),
found as the equally active 5-HT6R agent, as well as the most se-
lective phenyl-unsubstituted compound 2 seem to be worth of
wider considerations, too. Thus, the presented results set the new
lead structures for further studies concerning search for 5-HT6R
agents, which may be a useful tool for future treatment of cognitive
impairment associated with Alzheimer Disease.
4. Experimental
4.1. Chemical synthesis
Melting points (mp) were determined using MEL-TEMP II
apparatus and are uncorrected. 1H NMR and 13C NMR spectra were
recorded on a Varian Mercury-VX 400 MHz PFG instrument or FT-
NMR JEOL (JNM-ECZR500 RS1 v. ECZR) 500 MHz instrument (13C
NMR for 3e20) in DMSO‑d6 (for almost all compounds, except from
compound 2e400 MHz) at ambient temperature using the solvent
signal as an internal standard: the values of the chemical shifts
expressed as d values in (ppm) and the coupling constants (J) in Hz.
Data are reported as follows: chemical shift, multiplicity (s, singlet;
br. s, broad singlet; d, doublet; t, triplet; dd, doublet of doublet, q,
quintet, m, multiplet), coupling constant J, number of protons,
Fig. 9. Illustration of the binding modes of selected 1,3,5-triazine derivatives with 5-HT6 receptor. (A) Comparison of the docking poses for compounds 9 (green), 12 (yellow), and
the lead structure 1 (cyan). (B) Binding modes of analogues with methyl (3epink), ethyl (4eblue), propyl (5ered), and butyl (6ebrown) linker branch. (C) Comparison of the binding
modes of unsubstituted 2 (orange) with its differently disubstituted of chlorine atoms derivatives, namely: 2,3-diCl (4eblue), 3,5-diCl (17eviolet), 2,5-diCl (9egreen), and 3,4-diCl
(14elimon). Amino acids that are crucial for the binding of the presented compounds are shown as thick dark-grey sticks. (For interpretation of the references to color in this figure
legend, the reader is referred to the Web version of this article.)
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ded on a UPLCeMS/MS system consisted of a Waters ACQUITY®
UPLC® (Waters Corporation, Milford, MA, USA) coupled to aWaters
TQD mass spectrometer (electrospray ionization mode ESI-tandem
quadrupole). The UPLC/MS purity of all the final compounds was
confirmed to be higher than 95% (except 14). Retention time values
(tR) are given in minutes. Thin-layer chromatography (TLC) was
performed on pre-coatedMerck silica gel 60 F254 aluminum sheets
(Hex/EtOAc 4:1, DCM/MeOH 95:5). The reactions at fixed temper-
ature were carried out using a magnetic stirrer with a contact
thermometer Heidolph MR 2001. Intermediates (22e40) were
synthesized based on previous methods [28e31], and used in a
crude form (purity 54e99%) for synthesis of the final compounds
(220). Details of their synthesis and chemical characterization are
provided in Supplementary.4.1.1. General procedure for the synthesis of final compounds
(220)
Sodium (10 mmol) was dissolved in 10 ml of absolute methanol,
then 4-methylpiperazine-1-yl biguanide hydrochloride (21)
(5 mmol) and a proper ester (22e40, 5 mmol) was added. The re-
action mixture was refluxed for 15e30 h. After cooling to room
temperature, the residuewaswashedwithwater (10ml), stirred for
30 min at room temperature. The precipitated product was isolated
by filtration and crystallized from methanol to give the desire finalproducts as solids (method A). In case of lack of desirable precipi-
tate, final product was converted into hydrochloric salt form using
solution of HCl in diethyl ether (method B).4.1.1.1. (RS)-4-(4-methylpiperazin-1-yl)-6-(1-phenoxypropyl)-1,3,5-
triazin-2-amine (2). Ester 22, reaction time: 16 h. Method A. White
solid. Yield 38%, LC/MSþ purity: 96,4%, tR ¼ 3.29, mp ¼ 112e114 C,
C17H24N6O (MW ¼ 328.42). 1H NMR (400 MHz, DMSO‑d6) d [ppm]:
0.97 (t, J ¼ 7.4 Hz, 3H, CH3), 1.84e1.93 (m, 2H, CH2), 2.17 (s, 3H,
NeCH3), 2.27 (br. s, 4H, Pip-3,5-H), 3.66 (br. s, 4H, Pip-2,6-H), 4.63
(t, J¼ 6.5 Hz,1H, OeCH), 6.77e6.89 (m, 4H, Ph-2,3,5,6-H), 7.00 (br. s,
1H, Ph-4-H), 7.18e7.24 (m, 2H, NH2). 13C NMR (101 MHz, DMSO‑d6)
d [ppm]: 10.50, 27.90, 42.86, 46.22, 54.70, 81.40, 115.56, 120.84,
129.78, 158.82, 164.94, 167.41, 176.51.4.1.1.2. (RS)-4-[1-(2,3-dichlorophenoxy)ethyl]-6-(4-methylpiperazin-
1-yl)-1,3,5-triazin-2-amine (3). Ester 23, reaction time: 15 h.
Method A. White solid. Yield 24%, LC/MSþ purity: 100%, tR ¼ 4.15,
mp ¼ 187e189 C, C16H20Cl2N6O (MW ¼ 383.28). 1H NMR
(500 MHz, DMSO‑d6) d [ppm]: 1.54 (d, J ¼ 5.73 Hz, 3H, CH3) 2.13 (s,
3H, NeCH3), 2.21 (br. s, 4H, Pip-3,5-H), 3.60 (br. s, 4H, Pip-2,6-H),
5.00 (d, J ¼ 6.30 Hz, 1H, OeCH), 6.68e6.99 (m, 2H, NH2), 6.87e6.89
(d def., 1H, Ph-6-H), 7.09e7.10 (m, 1H, Ph-5-H), 7.16 (t, J ¼ 7.20 Hz,
1H, Ph-4-H). 13C NMR (126 MHz, DMSO‑d6) d [ppm]: 20.72, 43.02,
46.25, 54.72, 77.63, 113.86, 120.93, 122.40, 128.67, 132.83, 155.71,
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4 .1.1. 3 . (RS ) -4 - [1 - (2 ,3 -d i ch lo rophenoxy )p ropyl ] -6 - (4-
methylpiperazin-1-yl)-1,3,5-triazin-2-amine (4). Ester 24, reaction
time: 21 h. Method A. White solid. Yield 40%, LC/MSþ purity: 100%,
tR ¼ 4.73, mp ¼ 174e176 C, C17H22Cl2N6O (MW ¼ 397.30). 1H NMR
(500 MHz, DMSO‑d6) d [ppm]: 1.02 (t, J ¼ 7.4 Hz, 3H, CH3), 1.97 (p,
J ¼ 7.3 Hz, 2H, CH2), 2.16 (s, 3H, NeCH3), 2.25 (br. s, 4H, Pip-3,5-H),
3.63 (br. s, 4H, Pip-2,6-H), 4.80 (t, J ¼ 6.3 Hz, 1H, OeCH), 6.86e6.89
(m, 1H, Ph-6-H), 7.01 (br. s, 2H, NH2), 7.13e7.16 (m, 1H, Ph-5-H),
7.19e7.23 (m, 1H, Ph-4-H). 13C NMR (126 MHz, DMSO‑d6) d [ppm]:
10.38, 27.90, 46.26, 54.73, 82.57, 113.76, 120.91, 122.35, 128.75,
132.79, 155.93, 164.83, 167.41, 175.53.
4 .1.1. 4 . ( R S ) - 4 - [ 1 - ( 2 , 3 - d i c h l o rophenoxy ) bu t y l ] - 6 - ( 4 -
methylpiperazin-1-yl)-1,3,5-triazin-2-amine (5). Ester 25, reaction
time: 18 h. Method A. White solid. Yield 18%, LC/MSþ purity: 100%,
tR ¼ 5.20, mp ¼ 186e188 C, C18H24Cl2N6O (MW ¼ 411.33). 1H NMR
(500MHz, DMSO‑d6) d [ppm]: 0.89 (t, J¼ 6.8 Hz, 3H,CH3), 1.36e1.57
(m, 2H, CH2), 1.78e1.98 (m, 2H, CH2), 2.12 (s, 3H, NeCH3), 2.21 (s,
2H, Pip-3,5-H), 2.46 (s, 2H, Pip-3,5-H), 3.59 (s, 4H, Pip-2,6-H),
4.76e4.88 (m, 1H, OeCH), 6.77e6.91 (m, 2H, NH2), 6.98 (br. s, 1H,
Ph-5-H), 7.07e7.23 (m, 2H, Ph-4,6-H). 13C NMR (126 MHz,
DMSO‑d6) d [ppm]: 14.23, 18.81, 36.69, 46.26, 54.71, 81.17, 113.67,
120.86, 122.35, 128.76, 132.80, 155.91, 164.83, 167.41, 175.75.
4 .1.1.5 . (RS)-4- [1- (2 ,3-d ich lorophenoxy)penthyl ] -6- (4-
methylpiperazin-1-yl)-1,3,5-triazin-2-amine (6). Ester 26, reaction
time: 19 h. Method A. White solid. Yield 52%, LC/MSþ purity: 98,5%,
tR ¼ 5.41, mp¼ 150e152 C, C19H26Cl2N6O (MW ¼ 425.36). 1H NMR
(500 MHz, DMSO‑d6) d [ppm]: 0.81 (t, J ¼ 7.16 Hz, 3H, CH3),
1.26e1.31 (q def., 2H, CH2), 1.37e1.48 (m, 2H, CH2), 1.85e1.95 (m,
2H, CH2), 2.11 (s, 3H, NeCH3) 2.20 (s, 4H, Pip-3,5-H), 3.31 (s, 4H, Pip-
2,6-H), 4.78e4.81 (d def., 1H, OeCH), 6.82 (d, J ¼ 7.45 Hz, 1H, Ph-6-
H), 6.99e7.01 (m, 2H, NH2), 7.09e7.10 (m,1H, Ph-5-H), 7.14e7.15 (m,
1H, Ph-4-H). 13C NMR (126 MHz, DMSO‑d6) d [ppm]: 14.42, 22.40,
27.68, 34.30, 43.20, 46.26, 54.72, 81.45, 113.68, 120.89, 122.35,
128.74, 132.81, 155.92, 164.84, 167.42, 175.73.
4.1.1.6. 4-[3-(2,3-dichlorophenoxy)propyl]-6-(4-methylpiperazin-1-
yl)-1,3,5-triazin-2-amine (7). Ester 27, reaction time: 20 h. Method
A. White solid. Yield 42%, LC/MSþ purity: 100%, tR ¼ 4.18,
mp ¼ 84e86 C, C17H22Cl2N6O (MW ¼ 397.30). 1H NMR (500 MHz,
DMSO‑d6) d [ppm]: 2.08 (d, J ¼ 6.30 Hz, 2H, CH2), 2.12 (br. s, 3H,
NeCH3), 2.21 (br. s, 4H, Pip-3,5-H), 2.53 (t, J ¼ 6.59 Hz, 2H, CH2),
3.61 (br. s, 4H, Pip-2,6-H), 4.09 (br. s, 2H, OeCH2), 6.74 (br. s, 2H,
NH2), 7.05 (d, J¼ 8.02 Hz, 1H, Ph-4-H), 7.14 (d, J¼ 8.02 Hz, 1H, Ph-6-
H), 7.23 (t, J ¼ 7.73 Hz, 1H, Ph-5-H). 13C NMR (126 MHz, DMSO‑d6)
d [ppm]: 26.58, 34.89, 42.85, 46.30, 54.85, 69.24, 112.69, 120.61,
122.34, 128.98, 132.77, 155.99, 164.96, 167.30, 177.16.
4.1.1.7. (RS)-4-[1-(2,5-dichlorophenoxy)ethyl]-6-(4-methylpiperazin-
1-yl)-1,3,5-triazin-2-amine (8). Ester 28, reaction time: 22 h.
Method A. White solid. Yield 43%, LC/MSþ purity: 96,4%, tR ¼ 4.02,
mp ¼ 153e155 C, C16H20Cl2N6O (MW ¼ 383.28). 1H NMR
(500 MHz, DMSO‑d6) d [ppm]: 1.53 (d, J ¼ 6.87 Hz, 3H, CH3), 2.12 (s,
3H, NeCH3), 2.21 (br. s, 4H, Pip-3,5-H), 3.61 (br. s, 4H, Pip-2,6-H),
5.01 (q, J ¼ 6.68 Hz, 1H, OeCH), 6.70e6.94 (m., 2H, NH2) 6.92e6.94
(d def., 1H, Ph-4-H), 7.06 (s, 1H, Ph-6-H), 7.37 (d, J¼ 8.02 Hz, 1H, Ph-
3-H). 13C NMR (126 MHz, DMSO‑d6) d [ppm]: 20.43, 43.09, 46.25,
54.75, 77.65, 115.77, 121.05, 121.74, 131.46, 132.38, 154.76, 164.82,
167.53, 175.91.
4 .1.1. 8 . (RS ) -4 - [1 - (2 ,5 -d i ch lo rophenoxy )p ropyl ] -6 - (4-
methylpiperazin-1-yl)-1,3,5-triazin-2-amine (9). Ester 29, reactiontime: 20 h. Method A. White solid. Yield 47%, LC/MSþ purity: 100%,
tR ¼ 4.60, mp¼ 163e165 C, C17H22Cl2N6O (MW¼ 397.30). 1H NMR
(500 MHz, DMSO‑d6) d [ppm]: 0.94 (t, J ¼ 7.45 Hz, 3H, CH3), 1.91 (q,
J ¼ 7.16 Hz, 2H, CH2), 2.11 (s, 3H, NeCH3), 2.21 (br. s, 4H, Pip-3,5-H),
3.61 (br. s, 4H, Pip-2,6-H), 4.77 (t, J¼ 6.30 Hz, 1H, OeCH), 6.84e6.90
(m, 2H, NH2), 6.90e6.93 (d def., 1H, Ph-6-H), 7.02e7.05 (d def., 1H,
Ph-4-H), 7.36 (d, J ¼ 8.59 Hz, 1H, Ph-3-H). 13C NMR (126 MHz,
DMSO‑d6) d [ppm]: 10.25, 27.60, 43.11, 46.23, 54.74, 82.69, 115.66,
121.11, 121.66, 131.41, 132.39, 155.01, 164.79, 167.49, 175.23.
4 .1.1. 9 . ( R S ) - 4 - [ 1 - ( 2 , 5 - d i c h l o r ophenoxy ) bu t y l ] - 6 - ( 4 -
methylpiperazin-1-yl)-1,3,5-triazin-2-amine (10). Ester 30, reaction
time: 22 h. Method A. White solid. Yield 54%, LC/MSþ purity: 96,7%,
tR ¼ 5.13, mp ¼ 143e145 C, C18H24Cl2N6O (MW ¼ 411.33). 1H NMR
(500MHz, DMSO‑d6) d [ppm]: 0.92 (t, J¼ 7.4 Hz, 3H, CH3),1.37e1.55
(m, 2H, CH2),1.83e2.00 (m, 2H, CH2), 2.16 (s, 3H, NeCH3), 2.25 (br. s,
4H, Pip-3,5-H), 3.57e3.74 (m, 4H, Pip-2,6-H), 4.88 (dd, J1 ¼ 8.2 Hz,
J2 ¼ 4.9 Hz, 1H, OeCH), 6.90e6.94 (m, 1H, NH2), 6.96e6.98 (m, 1H,
Ph-6-H), 7.05 (d, J ¼ 2.3 Hz, 1H, Ph-4-H), 7.06e7.09 (m, 1H, NH2),
7.41e7.44 (m, 1H, Ph-3-H). 13C NMR (126 MHz, DMSO‑d6) d [ppm]:
175.43, 167.46, 164.77, 154.97, 132.37, 131.47, 121.70, 121.05, 115.60,
81.24, 54.74, 46.27, 36.38, 18.70, 14.25.
4.1.1.10 . (RS)-4-[1-(2 ,5-dich lorophenoxy)penthyl ]-6-(4-
methylpiperazin-1-yl)-1,3,5-triazin-2-amine (11). Ester 31, reaction
time: 25 h. Method A. White solid. Yield 33%, LC/MSþ purity: 98,8%,
tR¼ 5.34, mp¼ 143e145 C, C19H26Cl2N6O (MW¼ 425.36). 1H NMR
(500 MHz, DMSO‑d6) d [ppm]: 0.80 (t, J ¼ 7.16 Hz, 3H, CH3),
1.24e1.32 (m, 2H, CH2), 1.35e148 (m, 2H, CH2), 1.85e1.96 (m, 2H,
CH2), 2.11 (s, 3H, NeCH3), 2.20 (br. s, 4H, Pip-3,5-H), 3.61 (br. s, 4H,
Pip-2,6-H), 4.80e4.83 (m, 1H, OeCH), 6.84e6.92 (m, 2H, NH2),
6.90e6.92 (m,1H, Ph-6-H), 7.01 (d, J¼ 2.29 Hz, 1H, Ph-4-H), 7.36 (d,
J ¼ 8.02 Hz, 1H, Ph-3-H). 13C NMR (126 MHz, DMSO‑d6) d [ppm]:
14.39, 22.42, 27.58, 34.02, 43.02, 46.23, 54.75, 81.56, 115.60, 121.08,
121.65, 131.41, 132.40, 154.98, 164.79, 167.50, 175.41.
4.1.1.11. 4-[3-(2,5-dichlorophenoxy)propyl]-6-(4-methylopiperazin-
1-yl)-1,3,5-triazin-2-amine (12). Ester 32, reaction time: 16 h.
Method A. White solid. Yield 28%, LC/MSþ purity: 98,8%, tR ¼ 3.71,
mp ¼ 126e128 C, C17H22Cl2N6O (MW ¼ 397.30). 1H NMR
(500 MHz, DMSO‑d6) d [ppm]: 2.05e2.06 (m, 2H, CH2), 2.12 (br. s,
3H, NeCH3), 2.21 (br. s, 4H, Pip-3,5-H), 2.50 (t, J ¼ 7.16 Hz, 2H, CH2),
3.62 (br. s, 4H, Pip-2,6-H), 4.09 (t, J ¼ 6.01 Hz, 2H, OeCH2), 6.70 (br.
s, 2H, NH2), 6.94e6.96 (m, 1H, Ph-4-H), 7.16 (s, 1H, Ph-6-H), 7.37 (d,
J ¼ 8.59 Hz, 1H, Ph-3-H). 13C NMR (126 MHz, DMSO‑d6) d [ppm]:
26.56, 34.81, 42.87, 46.31, 54.86, 69.14,114.50,120.80,121.58,131.32,
132.94, 155.14, 164.97, 167.30, 177.14.
4 .1.1.12 . (RS ) -4 - [1 - (3 , 4 -d i ch l o rophenoxy ) e thy l ] -6 - (4 -
methylopiperazin-1-yl)-1,3,5-triazin-2-amine hydrochloride (13).
Ester 33, reaction time: 30 h. Method B. White solid. Yield 13%, LC/
MSþ purity: 100%, tR ¼ 4.28, mp ¼ 258e260 C, C16H20Cl2N6O
(MW ¼ 383.11). 1H NMR (500 MHz, DMSO‑d6) d [ppm]: 1.55 (d,
J¼ 6.87 Hz, 3H, CH3), 2.70 (br. s, 3H, NeCH3), 3.03 (br. s, 4H, Pip-3,5-
H), 4.55e4.63 (m, 4H, Pip-2,6-H), 5.31 (d, J ¼ 6.30 Hz, 1H, OeCH),
7.06e7.08 (m, 1H, Ph-6-H), 7.38e7.39 (m, 1H, Ph-2-H), 7.48e7.49
(m, 1H, Ph-5-H), 8.18e8.36 (m, 2H, NH2), 11.85 (br. s, 1H, NHþ). 13C
NMR (126 MHz, DMSO‑d6) d [ppm]: 19.67, 42.44, 51.69, 51.91, 74.69,
116.98, 118.55, 123.87, 131.49, 132.01, 156.82, 162.80.
4 .1.1.13 . (RS)-4- [1- (3 ,4-d ich lorophenoxy)propyl ] -6- (4-
methylopiperazin-1-yl)-1,3,5-triazin-2-amine (14). Ester 34, reac-
tion time: 20 h. Method A. White solid. Yield 50%, LC/MSþ purity:
91,4%, tR¼ 4.61, mp¼ 126e128 C, C17H22Cl2N6O (MW¼ 397.30). 1H
NMR (500 MHz, DMSO‑d6) d [ppm]: 0.90 (t, J ¼ 7.45 Hz, 3H, CH3),
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3,5-H), 3.61 (br. s, 4H, Pip-2,6-H), 4.67 (t, J ¼ 6.30 Hz, 1H, OeCH),
6.82e6.84 (m, 1H, Ph-6-H), 6.82e7.00 (m, 2H, NH2), 7.12 (s, 1H, Ph-
2-H), 7.40 (d, J¼ 9.16 Hz,1H, Ph-3-H). 13C NMR (126MHz, DMSO‑d6)
d [ppm]: 10.34, 27.64, 43.11, 46.26, 54.73, 81.99, 116.52, 117.74,
122.80, 131.36, 131.81, 158.35, 164.85, 167.42, 175.57.
4.1.1.14. 4-[3-(3,4-dichlorophenoxy)propyl]-6-(4-methylopiperazin-
1-yl)-1,3,5-triazin-2-amine (15). Ester 35, reaction time: 18 h.
Method A. White solid. Yield 45%, LC/MSþ purity: 99,2%, tR ¼ 3.91,
mp ¼ 90e92 C, C17H22Cl2N6O (MW ¼ 397.30). 1H NMR (500 MHz,
DMSO‑d6) d [ppm]: 2.01e2.03 (m, 2H, CH2), 2.12 (s, 3H, NeCH3),
2.20 (br. s, 4H, Pip-3,5-H), 2.46e2.47 (m, 2H, CH2), 3.61 (br. s, 4H,
Pip-2,6-H), 3.98 (t, J ¼ 6.01 Hz, 2H, OeCH2), 6.74 (br. s, 2H, NH2),
6.86e6.89 (m, 1H, Ph-6-H), 7.12 (d, J¼ 2.29 Hz, 1H, Ph-2-H), 7.42 (d,
J ¼ 9.16 Hz, 1H, Ph-3-H). 13C NMR (126 MHz, DMSO‑d6) d [ppm]:
26.60, 34.85, 42.85, 46.29, 54.84, 68.40, 115.89, 116.80, 122.72,
131.40, 132.09, 158.62, 164.94, 167.29, 177.19.
4 .1.1.15 . ( RS ) -4 - [1 - (3 , 5 -d i ch l o rophenoxy ) e thy l ] -6 - (4 -
methylopiperazin-1-yl)-1,3,5-triazin-2-amine (16). Ester 36, reac-
tion time: 20 h. Method A. White solid. Yield 29%, LC/MSþ purity:
100%, tR ¼ 4.33, mp ¼ 180e182 C, C16H20Cl2N6O (MW ¼ 383.28).
1H NMR (500 MHz, DMSO‑d6) d [ppm]: 1.48 (d, J ¼ 6.30 Hz, 3H,
CH3), 2.12 (s, 3H, NeCH3), 2.21 (s, 4H, Pip-3,5-H), 3.31 (s, 4H, Pip-
2,6-H), 4.96 (q, J ¼ 6.30 Hz, 1H, OeCH), 6.88 (br. s, 2H, NH2), 6.93 (d,
J ¼ 1.72 Hz, 2H, Ph-2,6-H), 7.03 (s, 1H, Ph-4-H). 13C NMR (126 MHz,
DMSO‑d6) d [ppm]: 20.40, 42.90, 46.25, 54.74, 77.03, 115.13, 120.74,
134.86, 160.00, 164.86, 167.50, 176.09.
4 .1.1.16 . (RS)-4- [1- (3 ,5-d ich lorophenoxy)propyl ] -6- (4-
methylpiperazin-1-yl)-1,3,5-triazin-2-amine (17). Ester 37, reaction
time: 16 h. Method A. White solid. Yield 48%, LC/MSþ purity: 100%,
tR ¼ 4.90, mp¼ 124e126 C, C17H22Cl2N6O (MW¼ 397.30). 1H NMR
(500MHz, DMSO‑d6) d [ppm]: 0.95 (t, J¼ 7.4 Hz, 3H, CH3),1.88e1.95
(m, 2H, CH2), 2.16 (s, 3H, NeCH3), 2.25 (br. s, 4H, Pip-3,5-H),
3.54e3.76 (br. s, 4H, Pip-2,6-H), 4.77 (t, J ¼ 6.5 Hz, 1H, OeCH), 6.91
(br. s, 1H, NH2), 6.97 (d, J ¼ 1.8 Hz, 2H, Ph-2,6-H), 7.03 (br. s, 1H,
NH2), 7.10 (t, J ¼ 1.8 Hz, 1H, Ph-4-H). 13C NMR (126 MHz, DMSO‑d6)
d [ppm]: 10.29, 27.48, 46.27, 54.76, 82.09, 115.16, 120.74, 134.85,
160.33, 164.81, 167.42, 175.35.
4 .1.1.17 . (RS ) -4- [1 - (3 , 5 -d i ch lo rophenoxy )bu ty l ] -6 - (4 -
methylpiperazin-1-yl)-1,3,5-triazin-2-amine (18). Ester 38, reaction
time: 21 h. Method A. White solid. Yield 46%, LC/MSþ purity: 98,3%,
tR ¼ 5.26, mp ¼ 164e166 C, C18H24Cl2N6O (MW ¼ 411.33). 1H NMR
(500MHz, DMSO‑d6) d [ppm]: 0.90 (t, J¼ 7.3 Hz, 3H, CH3), 1.31e1.49
(m, 2H, CH2), 1.79e1.91 (m, 2H, CH2), 2.16 (s, 3H, NeCH3), 2.25 (br. s,
4H, Pip-3,5-H), 3.63 (br. s, 4H, Pip-2,6-H), 4.83 (dd, J1 ¼ 7.8 Hz,
J2 ¼ 5.2 Hz, 1H, OeCH), 6.91 (br. s, 1H, NH2), 6.94e6.97 (m, 2H, Ph-
2,6-H), 7.03 (br. s, 1H, NH2), 7.07e7.10 (m, 1H, Ph-4-H). 13C NMR
(126MHz, DMSO‑d6) d [ppm]: 175.57, 167.42, 164.81, 160.30, 134.86,
120.75, 115.12, 80.65, 54.73, 46.26, 36.34, 18.72, 14.21.
4 .1.1.18 . (RS) -4- [1- (3 ,5-d i ch lorophenoxy)pentyl ] -6- (4-
methylpiperazin-1-yl)-1,3,5-triazin-2-amine (19). Ester: 39, reaction
time: 22 h. Method A. White solid. Yield 44%, LC/MSþ purity: 99,5%,
tR ¼ 5.70, mp¼ 154e156 C, C19H26Cl2N6O (MW¼ 425.36). 1H NMR
(500MHz, DMSO‑d6) d [ppm]: 0.86 (t, J¼ 5.4 Hz, 3H, CH3),1.25e1.46
(m, 4H, CH2eCH2), 1.84e1.93 (m, 2H, CH2), 2.16 (s, 3H, NeCH3), 2.25
(s, 4H, Pip-3,5-H), 3.64 (s, 4H, Pip-2,6-H), 4.79e4.84 (m, 1H, OeCH),
6.91 (br. s, 1H, NH2), 6.95e6.98 (m, 2H, Ph-2,6-H), 7.04 (br. s, 1H,
NH2), 7.08e7.11 (m, 1H, Ph-4-H). 13C NMR (126 MHz, DMSO‑d6)
d [ppm]: 14.40, 22.42, 27.55, 33.98, 46.21, 54.74, 80.90, 115.12,
120.75, 134.86, 160.29, 164.80, 167.43, 175.55.4.1.1.19. 4-[3-(2,4-dichlorophenoxy)propyl]-6-(4-methylpiperazin-1-
yl)-1,3,5-triazin-2-amine (20). Ester 40, reaction time: 17 h. Method
A. White solid. Yield 43%, LC/MSþ purity: 100%, tR ¼ 4.09,
mp ¼ 150e152 C, C17H22Cl2N6O (MW ¼ 397.30). 1H NMR
(500 MHz, DMSO‑d6) d [ppm]: 2.06e2.07 (m, 2H, CH2), 2.12 (br. s,
3H, NeCH3), 2.21 (br. s, 4H, Pip-3,5-H), 2.52 (br. s, 2H, CH2), 3.62 (br.
s, 4H, Pip-2,6-H), 4.06 (br. s, 2H, OeCH2), 6.73 (br. s, 2H, NH2), 7.10
(br. s, 1H, Ph-6-H), 7.29 (br. s, 1H, Ph-5-H), 7.49 (br. s, 1H, Ph-3-H).
13C NMR (126 MHz, DMSO‑d6) d [ppm]: 26.56, 34.84, 42.85, 46.30,
54.86, 69.04, 115.46, 122.91, 124.75, 128.58, 129.73, 153.57, 164.97,
167.30, 177.15.
4.2. X-ray crystallographic studies
Crystals suitable for an X-ray structure analysis for both com-
pounds were obtained from methanol by slow evaporation of the
solvent at room temperature.
Data for single crystals were collected using the XtaLAB
Synergy-S diffractometer, equipped with the Cu (1.54184 Å) Ka
radiation source and graphite monochromator. The phase problem
was solved by direct methods using SIR-2014 [48] and all non-
hydrogen atoms were refined anisotropically using weighted full-
matrix least-squares on F2. Refinement and further calculations
were carried out using SHELXL [49]. The hydrogen atoms bonded to
carbons were included in the structure at idealized positions and
were refined using a riding model with Uiso(H) fixed at 1.5 Ueq(C)
for methyl groups and 1.2 Ueq(C) for the other hydrogen atoms.
Hydrogen atoms attached to nitrogen atoms were found from the
difference Fourier map and refined without any restraints. For
molecular graphics MERCURY [50] program was used.
Crystallographic data for 9: C17H22Cl2N6O, Mr ¼ 397.30,
wavelength 1.54184 Å, crystal size ¼ 0.13  0.18  0.60 mm3,
triclinic, space group Pı, a ¼ 8.6624(3) Å, b ¼ 9.8661(4) Å,
c ¼ 12.2609(5) Å, a ¼ 70.529(4), b ¼ 77.394(3), g ¼ 86.601(3),
V ¼ 964.02(7) Å3, Z ¼ 2, T ¼ 100(2) K, 25842 reflections collected,
3867 unique reflections (Rint ¼ 0.0301), R1 ¼ 0.0314, wR2 ¼ 0.0777
[I > 2s(I)], R1 ¼ 0.0325, wR2 ¼ 0.0786 [all data].
Crystallographic data for 20: C17H22Cl2N6O, Mr ¼ 397.30,
wavelength 1.54184 Å, crystal size ¼ 0.08  0.15  0.39 mm3,
monoclinic, space group P21/n, a ¼ 15.5045(1) Å, b ¼ 6.4311(1) Å,
c ¼ 18.8146(5) Å, b ¼ 94.185(1), V ¼ 1871.02(3) Å3, Z ¼ 4,
T ¼ 100(2) K, 56835 reflections collected, 3876 unique reflections
(Rint ¼ 0.0391), R1 ¼ 0.0276, wR2 ¼ 0.0727 [I > 2s(I)], R1 ¼ 0.0285,
wR2 ¼ 0.0733 [all data].
CCDC 1980289 and 1980290 contain the supplementary crys-
tallographic data. These data can be obtained free of charge from




The procedure of 5-HT6R homology models generation (b2
adrenergic receptor template), its use for analysis of the binding
mode of our other 1,3,5-triazine derivatives (to support structure-
activity relationship analyses) was described previously [31]. In
order to select the relevant subset of the 5-HT6 receptor confor-
mations, the newly synthesized compounds (2¡20) were docked
and analyzed. Only models showing coherent binding mode to the
previously described 1,3,5-triazine derivatives, and explaining the
main structure-activity relationships were used.
The three-dimensional structures of the synthesized com-
pounds were prepared using LigPrep [51], and the appropriate
ionization states at pH 7.4 ± 1.0 were assigned using Epik [52].
Protein Preparation Wizard was used to assign the bond orders,
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tion states for each receptor model. The receptor grids were
generated (OPLS3 force field [53]) by centering the grid box with a
size of 12 Å on the D3.32 residue. Docking was performed by
quantum-polarized ligand docking (QPLD) procedure [54] involves
the QM-derived ligand atomic charges in the protein environment
at the B3PW91/ccpVTZ level. Only the best ten poses per ligand
returned by the procedure were considered.
4.3.2. Binding free energy calculations
MM/GBSA (Generalized-Born/Surface Area) was used to calcu-
late the binding free energy based on the ligandereceptor com-
plexes generated by the QPLD procedure. The ligand poses were
minimized using the local optimization feature in Prime, the flex-
ible residue distance was set to 6.0 Å from a ligand pose, and the
ligand charges obtained in the QPLD stage were used. The energies
of complexes were calculated with the OPLS3e force field and
Generalized-Born/Surface Area continuum solvent model. To assess
the influence of a given substituent on the binding, the DDG was
calculated as a difference between binding free energy (DG) of
unsubstituted at phenyl ring and dichlorinated analogues.
4.4. Evaluation of 5-HT6R, 5-HT2AR, 5-HT7R, D2R affinities
4.4.1. Cell culture and preparation of cell membranes for
radioligand binding assays
HEK293 cells with stable expression of human 5-HT6, 5-HT7b
and D2L receptors (preparedwith the use of Lipofectamine 2000) or
CHOeK1 cells with plasmid containing the sequence coding for the
human serotonin 5-HT2A receptor (Perkin Elmer) were maintained
at 37 C in a humidified atmosphere with 5% CO2 and grown in
Dulbecco’s Modifier Eagle Medium containing 10% dialyzed fetal
bovine serum and 500 mg/ml G418 sulfate. For membrane prepa-
ration, cells were subcultured in 150 cm2 flasks, grown to 90%
confluence, washed twice with prewarmed to 37 C phosphate
buffered saline (PBS) and pelleted by centrifugation (200g) in PBS
containing 0.1 mM EDTA and 1 mM dithiothreitol. Prior to mem-
brane preparation, pellets were stored at 80 C.
4.4.2. Radioligand binding assays
Cell pellets were thawed and homogenized in 10 vol of assay
buffer using an Ultra Turrax tissue homogenizer and centrifuged
twice at 35,000 g for 15 min at 4 C, with incubation for 15 min at
37 C in between. The composition of the assay buffers was as
follows: for 5-HT2AR: 50 mM Tris HCl, 0.1 mM EDTA, 4 mM MgCl2
and 0.1% ascorbate; for 5-HT6R: 50 mM Tris HCl, 0.5 mM EDTA and
4 mM MgCl2, for 5- HT7bR: 50 mM Tris HCl, 4 mM MgCl2, 10 mM
pargyline and 0.1% ascorbate; for dopamine D2LR: 50 mM Tris HCl,
1 mM EDTA, 4 mM MgCl2, 120 mM NaCl, 5 mM KCl, 1.5 mM CaCl2
and 0.1% ascorbate. All assays were incubated in a total volume of
200 mL in 96-well microtitre plates for 1 h at 37 C, except 5-HT2AR
which were incubated at 27 C. The process of equilibration was
terminated by rapid filtration through Unifilter plates with a 96-
well cell harvester and radioactivity retained on the filters was
quantified on a Microbeta plate reader (PerkinElmer, USA). For
displacement studies the assay samples contained as radioligands
(PerkinElmer, USA): 1 nM [3H]-ketanserin (53.4 Ci/mmol) for 5-
HT2AR; 2 nM [3H]-LSD (83.6 Ci/mmol) for 5-HT6R; 0.8 nM [3H]-5-
CT (39.2 Ci/mmol) for 5-HT7R or 2.5 nM [3H]-raclopride (76.0 Ci/
mmol) for D2LR. Non-specific binding was defined with 10 mM of 5-
HT in 5-HT7R binding experiments, whereas 20 mM of mianserin,
10 mM of methiothepine or 10 mM of haloperidol were used in 5-
HT2AR, 5-HT6R and D2L assays, respectively. Each compound was
tested in triplicate at 7 concentrations (1010-104 M). The inhibi-
tion constants (Ki) were calculated from the Cheng-Prusoffequation [55]. Results were expressed as means of at least two
separate experiments.
4.5. Functional assays for 5-HT6 receptor
Test and reference compounds were dissolved in dimethyl
sulfoxide (DMSO) at a concentration of 10 mM. Serial dilutions
were prepared in 96-well microplate in assay buffer and 8 to 10
concentrations were tested. For the 5-HT6, adenylyl cyclase activity
were monitored using cryopreserved 1321N1 cells with expression
of the human serotonin 5-HT6 receptor (Perkin Elmer, USA).
Thawed cells were resuspended in stimulation buffer (HBSS, 5 mM
HEPES, 0.5 IBMX, and 0.1% BSA at pH 7.4) at 3  105 cells/ml. The
same volume (10 ml) of cell suspension was added to tested com-
pounds. Samples were loaded onto a white opaque half area 96-
well microplate. The antagonist response experiment was per-
formed with 22 nM serotonin as the reference agonist for 5-HT6
receptor. The agonist and antagonist were added simultaneously.
Cell stimulation was performed for 30 min at room temperature.
After incubation, cAMP measurements were performed with ho-
mogeneous TR-FRET immunoassay using the LANCE Ultra cAMP kit
(PerkinElmer, USA). 10 ml of EucAMP Tracer Working Solution and
10 ml of ULight-anti-cAMP Tracer Working Solution were added,
mixed, and incubated for 1 h. The TR-FRET signal was read on an
EnVision microplate reader (PerkinElmer, USA). IC 50 and EC 50




The following references used in ADMETox studies in vitro:
caffeine (CFN), carbonyl cyanide 3-chlorophenylhydrazone, (CCCP)
and doxorubicin (DX) were provided by Sigma-Aldrich (St. Louis,
MO, USA).
4.6.2. Permeability
Pre-coated PAMPA Plate System Gentest™ was used for esti-
mation of compounds passive transport through cell membranes
and was provided by Corning (Tewksbury, MA, USA). The assay was
performed in accordance to the manufacturer recommendations
and was previously described by our research group [32,34e38].
The concentrations in apical and basolateral wells were estimated
using the LC/MS method with an internal standard. The perme-
ability coefficient Pe was calculated according to the formulas
described in the literature [33] and compared to the high perme-
able reference CFN.
4.6.3. Metabolic stability
The in vitro evaluation of metabolic pathways was performed by
120 min incubation of compounds with rat liver microsomes
(RLMs) at 37 C according the described previously procedures
[32,34,35,37,38]. RLMs were provided by (Sigma-Aldrich, St. Louis,
MO, USA). The LC/MS analyses were performed to determine the
most probable structures of 5-HT6R ligands’ metabolites.
The in silico prediction of the most probable sites of metabolism
was performed by MetaSite 6.0.1. Software provided by Molecular
Discovery Ltd (Hertfordshire, UK).
4.6.4. Toxicity
Hepatoma HepG2 (ATCC® HB-8065™) cells were used for hep-
atotoxicity assessment. All assays and growth conditions were
applied as we described before [37e40]. Tested compounds were
added to the cells and incubated for 72 h in the four concentrations:
1, 10, 50 and 100 eM. The reference toxins CCCP and DXwere added
S. Sudoł et al. / European Journal of Medicinal Chemistry 203 (2020) 11252914at 10 mM and 1 mM, respectively. The cells’ viability was determined
by CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay
(MTS) provided by Promega (Madison, WI, USA). The absorbance
was measured using a microplate reader EnSpire (PerkinElmer,
Waltham, MA USA) at 490 nm.
4.7. In vivo studies
4.7.1. Animals
The experiments were performed on male Wistar rats
(230e260 g) obtained from an accredited animal facility at the
Jagiellonian University Medical College, Poland. The animals were
housed in group of four in controlled environment (ambient tem-
perature 21 ± 2 C; relative humidity 50e60%; 12-h light/dark cy-
cles (lights on at 8:00). Standard laboratory food (LSM-B) and
filtered water were freely available. Animals were assigned
randomly to treatment groups. All the experiments were per-
formed by two observers unaware of the treatment applied be-
tween 9:00 and 14:00 on separate groups of animals. All animals
were used only once. Procedures involving animals and their care
were conducted in accordance with current European Community
and Polish legislation on animal experimentation. Additionally, all
efforts were made to minimize animal suffering and to use only the
number of animals necessary to produce reliable scientific data. The
experimental protocols and procedures described in this manu-
script were approved by the I Local Ethics Commission in Cracow
(no 309/2019) and complied with the European Communities
Council Directive of 24 November 1986 (86/609/EEC) and were in
accordance with the 1996 NIH Guide for the Care and Use of Lab-
oratory Animals.
4.7.2. Drugs
All compounds were suspended in 1% Tween 80 immediately
before administration in a volume of 2 ml/kg. Compounds were
administered intraperitoneally (i.p.) 60 min while MK-801 was
given i.p. 30 min before testing. Control animals received vehicle
(1% Tween 80) according to the same schedule.
4.7.3. Behavioral procedures in rats
4.7.3.1. Novel object recognition (NOR) test and Novel Object Location
(NOL) test. Five days before the experiment, the rats were trans-
ferred to the laboratory, labeled and, thereafter, left to acclimate to
the new environment. The animals were handling every five days
before experiments to minimize the stress reaction. The protocol
was adapted from the original work [56,57]. The test session
comprising of two trials separated by an inter-trial interval (ITI) of
1 h was carried out on after two day of training session.
During the first trial (familiarization, T1) two identical objects
(A1 and A2) were presented in the opposite corners of the open
field, approximately 10 cm from the walls.
In the NOR test procedure:
During the second trial (recognition, T2) one of the A objects
was replaced by a novel object B, so that the animals were pre-
sented with the A ¼ familiar and B ¼ novel objects. Both trials
lasted for 3 min and the animals were returned to their home cages
after T1.
In the NOL test procedure:
During the second trial (recognition, T2) one of the A objects
was replaced to another place B, so that the animals were presented
with the A ¼ familiar location and B ¼ novel location of objects.
Both trials lasted for 3 min and the animals were returned to their
home cages after T1.
The objects used were the metal Coca-Cola cans and the glass
jars filled with the sand. The heights of the objects were compa-
rable (~12 cm) and the objects were heavy enough not to bedisplaced by the animals. The sequence of presentations and the
location of the objects was randomly assigned to each rat. After
each measurement, the floor was cleaned and dried.
The animals explored the objects by looking, licking, sniffing or
touching the object but not when leaning against, standing or
sitting on the object. Any rat exploring the two objects for less than
5 s within 3 min of T1 or T2 was eliminated from the study.
Exploration time of the objects was measured by blind experi-
menter. Based on exploration time (E) of two objects during T2,
discrimination index (DI) was calculated according to the formula:
DI¼ (EBeEA)/(EAþ AB). Using this metric, scores approaching zero
reflects no preference while positive values reflect preference for
the novel object (or novel location of object) and negative numbers
reflect preference for the familiar.
MK-801, used to attenuate learning, was administered at the
dose of 0.1 mg/kg (i.p.) 30 min before familiarization phase (T1),
while investigated compounds were given 60 min before T1
session.
4.7.4. Statistical analysis
The data of behavioral studies were evaluated by an analysis of
variance one-way ANOVA followed by Bonferroni’s post hoc test
(statistical significance set at p < 0.05).
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